Long-Acting Injectables Market: By Type (Small Molecule, Biologicals), By Application (Schizophrenia,   Diabetes, Oncology, Substance Abuse, Contraception, HIV, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

Long-Acting Injectables Market size was valued at USD 26,263.1 million in 2023 and is poised to grow at an 12.8% CAGR from 2024-2030. A long-acting injectable, also known as a depot injection, is a medication that is injected once or twice per month into the body to treat chronic conditions such as schizophrenia, bipolar disorder, and ankylosing spondylitis. They are given in a single injection, usually into the muscle, and release a steady dose of medication over a period of several weeks or months. The growth in this market can be attributed to the increasing prevalence of chronic diseases, the rising geriatric population, and technological advancements in the field of long acting injectables. Moreover, growing demand for schizophrenia and other psychotic disorders treatment around the world has a direct impact on the growth of the Long-Acting Injectables.

For instance, Janssen has been at the forefront of long-acting antipsychotics development with its Invega portfolio containing injectable Invega Sustenna, three-monthly injectable depot Invega Trinza, and the most recently approved twice-yearly Invega Hafyera for the treatment of schizophrenia generating a sales of USD 4.1 billion for Janssen in 2022. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in the long-acting injectables market. Additionally, the growing consumer demand presents avenues for market expansion. However, the high expenses associated with inventory management and the availability of alternate drug delivery methods are likely to hinder the market growth over the forecast period. Mental health disorders have been the focus of pharmaceutical companies across the world for several years and several big pharmaceutical companies have invested in R&D for antipsychotic drugs, HIV treatment, insulins etc. which are converted into long acting injectables.

Long-Acting Injectables Market Key Developments:

• In July, 2022, WHO released new guidelines for the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV and called for countries to consider this safe and highly effective prevention option for people at substantial risk of HIV infection.
• In April, 2024, Medincell and AbbVie today announced a collaboration to co-develop and commercialize up to six therapeutic products across several areas.